Michael E. Tenta (650) 843-5636 mtenta@cooley.com | Via EDGAR |
December 2, 2011
Securities and Exchange Commission
Attention: Jim B. Rosenberg
Lisa Vanjoske
Tabatha Akins
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Onyx Pharmaceuticals, Inc. |
| Form 10-K for Fiscal Year Ended December 31, 2010 |
| Filed February 23, 2011 |
| File No. 000-28298 |
Ladies and Gentlemen:
On behalf of Onyx Pharmaceuticals, Inc. (the “Company”), this letter is being submitted in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission by letter dated November 23, 2011, with respect to the Company’s Form 10-K for Fiscal Year Ended December 31, 2010.
Please be advised that the Company currently expects that it will provide its response to the Staff’s comment letter on or before December 22, 2011 and will further advise the Staff if it becomes unable to do so.
Please do not hesitate to contact me at (650) 843-5636 if you have any questions or would like any additional information regarding this matter.
Sincerely,
/s/ Michael E. Tenta
Michael E. Tenta
| cc: | Matthew K. Fust |
| Executive Vice President and Chief Financial Officer |
Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA 94306-2155 T: (650) 843-5000 F: (650) 849-7400 www.cooley.com